Cognitive Change, Inflammation, Neurodegenerative Diseases
Conditions
Brief summary
The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
Interventions
DIETARY_SUPPLEMENTTreatment
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo.
OTHERPlacebo
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo pill.
Sponsors
University of Rhode Island
National Institute of General Medical Sciences (NIGMS)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Identify as Female * Have a BMI of 18.5 or above * Must be able to swallow tablets
Exclusion criteria
* Those who are pregnant, breastfeeding, or taking hormone medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neurocognition | four weeks | NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics |
| Neurodegenerative disease panel | four weeks | BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1 |
| Markers of systemic inflammation | four weeks | GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα |
Countries
United States
Outcome results
None listed